Roth Mkm Reiterates Buy Rating for Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating reiterated by analysts at Roth Mkm in a report issued on Friday, Benzinga reports. They presently have a $40.00 price target on the stock.

Several other equities research analysts have also commented on MBRX. StockNews.com initiated coverage on shares of Moleculin Biotech in a research report on Friday, April 5th. They set a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Moleculin Biotech in a research report on Thursday, December 14th. Finally, Maxim Group decreased their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, March 26th.

Moleculin Biotech Stock Performance

Shares of NASDAQ MBRX opened at $4.63 on Friday. The firm has a market capitalization of $10.32 million, a P/E ratio of -0.34 and a beta of 1.95. Moleculin Biotech has a one year low of $4.34 and a one year high of $24.75. The company’s fifty day moving average is $7.33 and its two-hundred day moving average is $8.17.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new position in Moleculin Biotech in the 4th quarter valued at about $2,753,000. Renaissance Technologies LLC raised its stake in Moleculin Biotech by 34.7% in the 2nd quarter. Renaissance Technologies LLC now owns 127,400 shares of the company’s stock valued at $74,000 after purchasing an additional 32,795 shares during the last quarter. State Street Corp raised its stake in Moleculin Biotech by 19.2% in the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after purchasing an additional 11,497 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Moleculin Biotech during the 4th quarter valued at about $55,000. Finally, Atticus Wealth Management LLC acquired a new position in shares of Moleculin Biotech during the 4th quarter valued at about $43,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.